6533b82cfe1ef96bd128ed4c
RESEARCH PRODUCT
Linking Human Milk Oligosaccharides, Infant Fecal Community Types, and Later Risk To Require Antibiotics
Giuseppe PuccioNorbert SprengerAnnick MercenierNadine PortaLéa SiegwaldFrancis FoataPatrick DescombesPhilippe SteenhoutPhilippe AllietMichèle DelleyAline CharpagneBernard BergerDominik GrathwohlDeborah Moinesubject
Malefecal community types030309 nutrition & dieteticsmedicine.drug_classLNnTAntibioticsPhysiologyOligosaccharidesGut floraformulaMicrobiologyantibioticsHost-Microbe Biology03 medical and health sciencesFecesfluids and secretionsDouble-Blind MethodVirologyRNA Ribosomal 16SmicrobiotaMedicineHumansFeceshealth care economics and organizations030304 developmental biologyBifidobacterium0303 health sciencesbiologyBacteriaMilk Humanbusiness.industryInfant Newbornbiology.organism_classificationinfantInfant Formula2′FLQR1-502Anti-Bacterial AgentsGastrointestinal MicrobiomeClinical trialBifidobacteriaceaeBreast FeedingInfant formulaEnterotypeFemalehuman milk oligosaccharidesBifidobacteriumbusinessResearch Articledescription
Human milk is the sole and recommended nutrition for the newborn infant and contains one of the largest constituents of diverse oligosaccharides, dubbed human milk oligosaccharides (HMOs). Preclinical and clinical association studies indicate that HMOs have multiple physiological functions largely mediated through the establishment of the gut microbiome. Until recently, HMOs were not available to investigate their role in randomized controlled intervention trials. To our knowledge, this is the first report on the effects of 2 HMOs on establishing microbiota in newborn infants. We provide a detailed description of the microbiota changes observed upon feeding a formula with 2 HMOs in comparison to breastfed reference infants' microbiota. Then, we associate the microbiota to long-term health as assessed by prescribed antibiotic use.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2020-03-01 | mBio |